Study of Patients With Thrombotic Microangiopathy Associated With Mitomycin C, Treated or Not With Eculizumab

Inclusion Criteria

• •Adult patients (\>=18 years)
• •Having received treatment with mitomycin C (regardless of the method of administration and indication) between 01/01/1990 and 12/31/2023
• •and having developed a picture of thrombotic microangiopathy attributed to mitomycin C:
• •* biological: defined as: thrombocytopenia \<150G/L and mechanical hemolytic anemia (at least 3 out of 4 criteria: hemoglobin \< 12g/dL, presence of schistocytes in blood smear, LDH \> 1N, collapsed haptoglobin (\< lower limit of the limit of laboratory normal)
• •* or renal: pathological diagnosis of thrombotic microangiopathy on renal biopsy
• •having received or not treatment for the episode of microangiopathy, including or not complement inhibitors (Eculizumab).
• •Subject not opposing, after information, the reuse of their data for the purposes of this research